Edition:
United States

PTC Therapeutics Inc (PTCT.OQ)

PTCT.OQ on NASDAQ Stock Exchange Global Select Market

39.50USD
11:20am EDT
Change (% chg)

$2.95 (+8.07%)
Prev Close
$36.55
Open
$38.52
Day's High
$40.77
Day's Low
$38.50
Volume
292,595
Avg. Vol
392,768
52-wk High
$52.95
52-wk Low
$14.57

Select another date:

BUZZ-PTC Therapeutics: Jumps on deal to buy Agilis Biotherapeutics

** Drug developer's shares up nearly 9 pct at $40.07 in early trading on Friday

BRIEF-PTC Therapeutics Reports Q1 Loss Per Share $0.46

* PTC THERAPEUTICS REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS AND PROVIDES A CORPORATE UPDATE

BRIEF-PTC Therapeutics announces presentation of preliminary data from Part 1,dose finding portion, of ongoing FIREFISH clinical trial

* PRELIMINARY CLINICAL DATA FROM FIREFISH TRIAL IN TYPE 1 SMA PATIENTS PRESENTED AT THE AMERICAN ACADEMY OF NEUROLOGY ANNUAL MEETING

BRIEF-PTC Therapeutics Prices Public Offering Of Common Stock At $27.04 Per Share​

* PTC THERAPEUTICS ANNOUNCES PRICING OF PUBLIC OFFERING OF COMMON STOCK

BRIEF-PTC Therapeutics Announces Proposed Public Offering Of Common Stock

* PTC THERAPEUTICS ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK

BRIEF-Ptc Therapeutics Says ‍Firefish Study Of RG7916 In Type 1 Spinal Muscular Atrophy Patients Transitioned Into Pivotal Phase With Dosing First Patient​

* PTC THERAPEUTICS INC - ‍FIREFISH STUDY OF RG7916 IN TYPE 1 SPINAL MUSCULAR ATROPHY PATIENTS TRANSITIONED INTO PIVOTAL PHASE WITH DOSING FIRST PATIENT​ Source text for Eikon: Further company coverage:

BRIEF-PTC Therapeutics Q4 Revenue $78.0 Million

* ‍TOTAL REVENUES FOR Q4 OF 2017 WERE $78.0 MILLION COMPARED TO $25.2 MILLION IN Q4 OF 2016​

BRIEF-Boxer Capital Reports 6 Pct Passive Stake In ‍PTC Therapeutics​

* BOXER CAPITAL, LLC REPORTS 6 PERCENT PASSIVE STAKE IN ‍ PTC THERAPEUTICS, INC AS OF JANUARY 16, 2018 - SEC FILING​ Source text - http://bit.ly/2FkWr0i Further company coverage:

Select another date: